Podcast appearances and mentions of Paul S Jellinger

Dr. Jellinger joins the podcast to discuss the lipid section of the DCRM Multispecialty Practice Recommendations, as well the role of combination therapies and other concepts to lower LDL and what is coming next for the field of diabetes in 2022. 

Learn the latest in lipid lowering therapy in this extensive discussion with Dr. Paul S. Jellinger, MD, MACE, Professor of Medicine at the University of Miami and Chair of the writing committee for the American Association of Clinical Endocrinologists (AACE) 2017 Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease (CVD). Topics include ezetimibe, PCSK9, FOURIER trial, statin myopathy, CoQ10, fish oil, fibrates and more. For a more basic discussion of dyslipidemia check out episode #10. Full show notes are available at http://thecurbsiders.com/podcast Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Time Stamps 00:00 Intro 03:10 Rapid fire questions 08:15 Dyslipidemia defined 10:26 Classifying dyslipidemia 13:21 Diagnosing Familial Hypercholesterolemia 17:48 A difficult lipid case discussed 22:40 Lp (a), Apo B and LDL particle concentration 28:40 What labs to order 31:31 ACC/AHA versus other risk scores 38:21 IMPROVE-IT 41:35 Non-statin medications discussed 45:05 Hypertriglyceridemia fibrates and fish oil 48:25 How often to check the lipid panel 49:58 Statin Myopathy and CoQ10 54:17 FOURIER, PCSK9 and very low LDLs 59:43 Extreme risk category discussed 62:34 Is plaque regression possible? 64:12 Take home points 67:08 Outro Tags: assistant, care, cholesterol, doctor, education family, fish oil, foam, foamed, health, hospitalist, hospital, internal, internist, ldl, lipid, medicine, medical, myopathy, nurse, pcsk9, physician, practitioner, primary, statin, resident, student

Host: Farhad Zangeneh, MD Guest: Paul Jellinger In diabetes management, clinicians typically measure glycemic control with fasting plasma glucose (FPG) and premeal glucose measurements, and HbA1c. And, the goals for each of these measurements have been established based on the results of many clinical trials. However, the majority of patients with diabetes fail to achieve these glycemic goals. Elevated postprandial glucose (PPG) concentrations may contribute to suboptimal glycemic control. Host Dr Farhad Zangeneh is joined by Dr. Paul Jellinger who will address the issue of postprandial glucose and its complications. Paul S. Jellinger, MD and Master of the American College of Endocrinology (MACE) serves as Professor of Medicine on the voluntary faculty at the University of Miami and served as Chief of the Section of Endocrinology at Memorial Regional Hospital in Hollywood, Florida. Dr. Jellinger served as president of the AACE, the ACE and the Florida Endocrine Society. Dr. Jellinger has been active on the AACE Board of Directors.